About Us

Portage is a unique entity in the world of biotechnology, catalyzing R&D to produce more quality clinical programs and maximize potential returns. We do this by leveraging our development strategy and commercial insights, capitalizing on a deep network of industry relationships, and by eliminating typical overhead costs associated with many biotechnology companies. The end result is a viable product development strategy that supports commercial potential and company growth. Our organization is comprised of scientists, clinicians, and pharma experienced executives who have combined their passion for innovation with broad

business acumen, to create a better model for product development.

Portage facilitates delivery of the critical foundation that emerging biotechs need; funding, business and clinical counsel, and shared services that enable turnkey execution of commercially-informed development plans. We reduce the risks associated with early clinical development, and have successfully brought ideas to proof-of-concept via efficient capital management and a differentiated approach to scientific oversight, ultimately improving returns 10-30 fold.

news

Pipeline

COMPANY
ASSET
INDICATION
STAGE

Logo Iox

ASSET
IMM-60
IMM-65
INDICATION
Melanoma &
Lung Cancer
Bladder / Ovarian
STAGE
Planned Phase I/II
Planned Phase I/II

Logo Intensity

ASSET
INT230-6
INTXX
INDICATION
Solid Tumor
Solid Tumor
STAGE
Phase I/II
Preclinical

Logo Nekonal

ASSET
A
B
INDICATION
Heme Tumor
Solid Tumor
STAGE
IND-Enabling
IND-Enabling

Logo Rift

ASSET
A
INDICATION
Solid Tumor
STAGE
IND-Enabling

Logo Stimunity

ASSET
STING
STING
INDICATION
Solid Tumor
Solid Tumor
STAGE
IND-Enabling
Preclinical

Logo Saugatuck Ncomer

ASSET
PD1 + sm
PD1 + ap
INDICATION
Solid Tumor
Solid Tumor
STAGE
Preclinical
Preclinical
other companies:

Portage Pharmaceutical LogoSentien Logo

Management Team

Ian B Walters, MD, MBA - Chief Executive Officer and Director

Chief Executive Officer & Director

Dr. Walters has over 20 years of leadership and expertise in oncology/immunology drug development and specializes in the evaluation, prioritization and the innovation of new therapies for the treatment of severe diseases.

Robert Kramer, PhD - Chief Scientific Officer

Chief Scientific Officer

Robert Kramer has 24 years of experience in the pharmaceutical industry and is the former Head of Oncology Discovery Research at both Bristol-Myers Squibb and Janssen Pharmaceuticals.

Tenpo Steve

V.P. of Project Management & Operations

Steve Innaimo is a seasoned R&D expert who brings more than 25 years of experience in drug development from the large pharma, biotech and contract research organization sectors.

Board of Directors

Chairman & Director

Gregory Bailey is a co-founder and CEO of Juvanescence. Previously he was a …

Dr. Declan Doogan has over 30 years of industry experience in both major …

Director

Jim Mellon is an investor with interests in several industries and has worked …

Director

Steven Mintz has been a self-employed financial consultant since January …

Non-Executive Director

Kam Shah has more than 25 years of financial and management …